 To be considered evaluable for safety, the patient must receive at least 75 of their prescribed regimen per cycle for 4 consecutive cycles with a cycle of therapy defined as 28 days in the absence of disease progression or unacceptable toxicity. Patients who progress at 9 weeks evaluation or later but before completing 4 cycles and who have only experienced Grade 1 toxicities excluding alopecia will also be considered evaluable for safety. 